Key result
Eplerenone 50 mg or 100 mg daily added to enalapril significantly reduced UACR by 41.0% and 48.4%, respectively, compared to a 7.4% reduction with placebo (P<0.001), without increasing hyperkalemia.
Why the study?
Does eplerenone 50 or 100 mg/d added to enalapril reduce albuminuria in patients with type 2 diabetes?
Population
Patients with type 2 diabetes and a urinary albumin:creatinine ratio >= 50 mg/g, following an open-label…
Comparison
Eplerenone 50 mg or 100 mg oral once daily added… vs Matching placebo added to enalapril 20 mg/d for…
Design
RCT, randomly assigned, double-blind
Follow-up
12 weeks
Authors
Loading...
Supports adding low-dose eplerenone to enalapril for albuminuria reduction in type 2 diabetes without hyperkalemia risk; extends prior data to safer doses.
RCT
Double-blind
Randomized
Does eplerenone 50 or 100 mg/d added to enalapril reduce albuminuria in patients with type 2 diabetes?
Absolute Event Rate: 41% vs 7.4%
p-value: p=< 0.001
The addition of low-dose eplerenone (50 or 100 mg/day) to an ACE inhibitor significantly reduces albuminuria in patients with type 2 diabetes without significantly increasing the risk of hyperkalemia.
Epstein et al. (2006) conducted an RCT in Type 2 diabetes with albuminuria. Eplerenone (co-administered with enalapril) vs. Placebo (co-administered with enalapril) was evaluated on Percentage change from baseline at week 12 in UACR (p=< 0.001). Eplerenone 50 mg or 100 mg daily added to enalapril significantly reduced UACR by 41.0% and 48.4%, respectively, compared to a 7.4% reduction with placebo (P<0.001), without increasing hyperkalemia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: